Dechra buys rival to expand in EU
Dechra Pharmaceuticals, which makes medicines for pets and livestock, yesterday spent €135m (£112m) buying a smaller Dutch rival that makes drugs for cattle, horses, dogs, pigs, cats and chickens.
The market seemed to approve and shares in Dechra jumped more than 7 per cent. It will pay for Eurovet Animal Health with the proceeds of a £60m discounted rights issue, which is on a basis of three new shares for every 10 existing ones, and a new debt facility.
Dechra hopes to gain from Eurovet's reach in Europe. Eurovet has sales and marketing operations in the UK, the Netherlands, Germany, Belgium and Denmark, and supplies vets in more than 40 countries. Last year, its products, which include antibiotics, vitamins and anaesthetics, brought in sales of €76.8m.
Ian Page, Dechra's chief executive, said: "This is a great opportunity to build on the strong foundation we have created."
Shares in Dechra closed 34.5p higher at 498.5p.
- 1 Kylie Jenner challenge: Bizarre lip suction device inspired by Kardashian sister goes viral
- 2 Rarest Beanie Baby bought for just £10 at car boot sale could be sold for £62,500 on eBay
- 3 Katie Hopkins and The Sun editor are reported to police for incitement to racial hatred following migrant boat column
- 4 Bruce Forsyth backs assisted dying campaign: 'If I had Alzheimer's or dementia I would do something about it'
- 5 Giorgio Armani criticises the way some gay men dress saying 'a man has to be a man'
If I’m being racially abused I don’t need a stranger with a saviour complex to rescue me
The only black face in the Ukip manifesto is on the page about overseas aid
Ukip is the only main political party to not address LGBT rights in its manifesto
Food banks: One million Britons will soon be using them, according to Trussell Trust
Religion isn't growing, it is becoming vigorous in its demise, says philosopher AC Grayling
BBC election debate: The one photo that summed up the whole 90-minute leaders debate
iJobs Money & Business
£30 - 35k (DOE): Guru Careers: We are seeking a Pricing Analyst with experienc...
£24000 - £26000 per annum + benefits : Ashdown Group: A highly successful, glo...
£21000 - £24000 per annum: Ashdown Group: The Ashdown Group has been engaged b...
£45000 - £50000 per annum + benefits : Ashdown Group: A highly successful, int...